Logo

KIDS

OrthoPediatrics Corp.

KIDS

OrthoPediatrics Corp. • NASDAQ
$18.49 ▼ -0.54% (-0.10)
Market Cap $463.68 M
52w High $27.60
52w Low $15.28
Dividend Yield 0%
P/E -9.43
Volume 78.12K
Outstanding Shares 25.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $61.25M ▲ $50.14M ▼ $-11.773M ▼ -19.221% ▼ $-0.5 ▼ $-4.777M ▼
Q2-2025 $61.082M ▲ $54.676M ▲ $-7.113M ▲ -11.645% ▲ $-0.3 ▲ $-778K ▲
Q1-2025 $52.411M ▼ $49.203M ▼ $-10.659M ▲ -20.337% ▲ $-0.46 ▲ $-4.289M ▲
Q4-2024 $52.667M ▼ $49.62M ▲ $-16.069M ▼ -30.511% ▼ $-0.69 ▼ $-4.573M ▼
Q3-2024 $54.573M $45.626M $-7.919M -14.511% $-0.34 $-3.453M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $57.728M ▼ $493.486M ▼ $144.177M ▼ $349.309M ▼
Q2-2025 $70.149M ▲ $503.606M ▲ $148.092M ▲ $355.514M ▲
Q1-2025 $58.772M ▼ $470.25M ▼ $123.104M ▲ $347.146M ▼
Q4-2024 $68.833M ▼ $473.209M ▼ $118.643M ▲ $354.566M ▼
Q3-2024 $76.064M $489.294M $118.375M $370.919M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.773M ▼ $-581K ▲ $-26.838M ▼ $-282K ▼ $-27.721M ▼ $-3.42M ▲
Q2-2025 $-7.113M ▲ $-10.462M ▼ $-3.545M ▲ $24.8M ▲ $11.176M ▲ $-13.907M ▼
Q1-2025 $-10.659M ▲ $-4.156M ▼ $-5.987M ▼ $-126K ▲ $-10.348M ▼ $-8.383M ▼
Q4-2024 $-16.069M ▼ $-3.987M ▲ $-2.412M ▲ $-541K ▼ $-7.268M ▼ $-3.725M ▲
Q3-2024 $-7.919M $-10.279M $-26.768M $58.518M $22.155M $-11.66M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Spine
Spine
 $30.00M ▲$10.00M ▼$20.00M ▲$20.00M ▲
Sports Medicine And Other
Sports Medicine And Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Trauma And Deformity
Trauma And Deformity
 $0 ▲$40.00M ▲$40.00M ▲$40.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past five years, and the core business is clearly growing. The company maintains healthy product margins, which suggests its specialized devices can command attractive pricing. However, operating costs still run higher than gross profit, so the business remains loss‑making overall. Losses have widened again in the most recent year after a brief improvement, showing that scaling revenue alone has not yet translated into consistent profitability. The story here is solid top‑line growth, but with a cost base and investment level that continue to weigh on the bottom line.

Balance Sheet

Balance Sheet The balance sheet shows a business that has been building up its asset base and shareholder equity over time, consistent with a company investing for growth. Cash has improved from earlier years but remains relatively limited, so liquidity is adequate but not abundant. Debt was minimal until recently, when borrowings increased, likely to support expansion or acquisitions. While leverage is still manageable, the shift from almost no debt to a noticeable level is a key trend to watch, especially as the company is not yet profitable.

Cash Flow

Cash Flow Cash flow from day‑to‑day operations has been negative for several years, which means the company is still consuming cash rather than generating it. Free cash flow is also consistently negative, reflecting both operating losses and ongoing investment in equipment, instruments, and technology. Capital spending itself is not excessive, but when combined with operating outflows, it creates a persistent cash burn that needs to be covered by cash on hand, debt, or equity raises. The path to self‑funded growth is not yet in place, so continued access to capital is important.

Competitive Edge

Competitive Edge OrthoPediatrics operates in a very narrow and specialized niche: orthopedic devices designed specifically for children. This exclusive focus gives it a meaningful edge over general orthopedic players that mostly adapt adult products. The company offers a broad range of pediatric systems and has deep relationships with children’s hospitals and leading pediatric surgeons, reinforced by a dedicated, specialized sales and education effort. These factors create a strong, differentiated position, but the niche nature of the market also means growth depends heavily on procedure volumes, hospital budgets, and the pace at which surgeons adopt its specialized solutions.

Innovation and R&D

Innovation and R&D Innovation is a clear centerpiece of the strategy. The company has moved beyond implants into enabling technologies such as radiation‑free navigation for spine surgery, 3D‑printed guides, and digital planning tools. Its pipeline includes platforms for surgical workflow optimization, robotic assistance, and non‑invasive growth‑friendly systems for spinal deformities—many targeted at conditions where existing treatments are imperfect. Partnerships and tuck‑in acquisitions help expand the portfolio into rare and complex pediatric conditions. The upside is strong clinical differentiation and potential new revenue streams; the risk is that these projects require ongoing spending and may take time to achieve broad adoption and commercial scale.

Summary

Overall, OrthoPediatrics combines a clear growth story and a distinctive niche with the typical financial profile of an emerging medical device platform: rising revenue and a stronger product portfolio, but continuing losses, negative cash flow, and a recent step‑up in debt. Its specialized pediatric focus, strong surgeon relationships, and technology pipeline are meaningful strategic strengths. At the same time, the company’s reliance on external capital, the need to prove sustainable profitability, and execution risk around new product launches and integrations are important considerations when assessing its long‑term trajectory.

NEWS

November 13, 2025 · 7:00 AM UTC

OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches

Read more

November 4, 2025 · 4:05 PM UTC

OrthoPediatrics to Participate in Upcoming Conferences

Read more

October 28, 2025 · 4:05 PM UTC

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results

Read more

October 28, 2025 · 4:04 PM UTC

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family

Read more

October 15, 2025 · 4:05 PM UTC

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025

Read more